Protagonist Therapeutics Inc (PTGX)
46.46
+4.81
(+11.55%)
USD |
NASDAQ |
Nov 22, 16:00
46.00
-0.46
(-0.99%)
After-Hours: 05:13
Protagonist Therapeutics Revenue (Quarterly): 4.675M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 4.675M |
| June 30, 2024 | 4.167M |
| March 31, 2024 | 254.95M |
| December 31, 2023 | 60.00M |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | 0.859M |
| March 31, 2022 | 25.72M |
| December 31, 2021 | 8.617M |
| September 30, 2021 | 10.29M |
| June 30, 2021 | 2.265M |
| March 31, 2021 | 6.189M |
| Date | Value |
|---|---|
| December 31, 2020 | 5.65M |
| September 30, 2020 | 13.11M |
| June 30, 2020 | 6.217M |
| March 31, 2020 | 3.647M |
| December 31, 2019 | 2.719M |
| September 30, 2019 | 4.141M |
| June 30, 2019 | -8.189M |
| March 31, 2019 | 1.56M |
| December 31, 2018 | 2.353M |
| September 30, 2018 | 6.117M |
| June 30, 2018 | 11.67M |
| March 31, 2018 | 10.78M |
| December 31, 2017 | 11.28M |
| September 30, 2017 | 8.781M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.859M
Minimum
Jun 2022
254.95M
Maximum
Mar 2024
27.27M
Average
6.189M
Median
Mar 2021
Revenue (Quarterly) Benchmarks
| Johnson & Johnson | 22.47B |
| Assembly Biosciences Inc | 6.845M |
| Precision BioSciences Inc | 0.576M |
| Entrada Therapeutics Inc | 19.57M |
| NovaBay Pharmaceuticals Inc | 2.441M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -33.21M |
| Total Expenses (Quarterly) | 46.13M |
| EPS Diluted (Quarterly) | -0.54 |
| Enterprise Value | 2.300B |
| Profit Margin (Quarterly) | -710.4% |
| Earnings Yield | 5.73% |
| Operating Earnings Yield | 5.20% |
| Normalized Earnings Yield | 5.725 |